SANOFI

Sanofi India Limited

Indian arm of global biopharma Sanofi, focused on diabetes and vaccines

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

sanofi.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹2942.10
Market cap
6,767 Cr
Stock P/E
20.9
P/B
8.19
Dividend yield
6.5%
ROE (year to Dec 2024)
48.0%
ROCE (year to Dec 2024)
65.5%
Operating margin (year to Dec 2024)
22.6%
OCF / EBITDA (year to Dec 2025)
89.2%
OCF / EBITDA (3Y)
63.3%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Sanofi India sells branded medicines in India, led by diabetes insulins such as Lantus, Toujeo and Soliqua, and runs a legacy cardiovascular, central nervous system and oral anti-diabetes portfolio through partners.

Company snapshot

53rdBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 20.5% — the business keeps a healthy share of every rupee it earns.
3 more signals from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales715 Cr694 Cr732 Cr464 Cr524 Cr515 Cr536 Cr406 Cr475 Cr420 Cr472 Cr438 Cr
Operating expenses (approx.)506 Cr507 Cr514 Cr348 Cr404 Cr397 Cr364 Cr311 Cr341 Cr330 Cr330 Cr322 Cr
EBITDA208 Cr187 Cr219 Cr116 Cr120 Cr118 Cr172 Cr95 Cr134 Cr90 Cr143 Cr115 Cr
OPM %29.2%27.0%29.9%25.0%22.8%23.0%32.1%23.4%28.2%21.5%30.2%26.3%
Other income12 Cr12 Cr7 Cr5 Cr2 Cr6 Cr3 Cr9 Cr5 Cr3 Cr4 Cr6 Cr
Interest0.32 Cr0.40 Cr0.30 Cr0.40 Cr0.40 Cr0.40 Cr0.30 Cr0.40 Cr0.40 Cr0.60 Cr0.30 Cr0.30 Cr
Depreciation10 Cr10 Cr10 Cr9 Cr9 Cr10 Cr10 Cr9 Cr9 Cr10 Cr9 Cr9 Cr
Profit before tax210 Cr189 Cr188 Cr139 Cr113 Cr122 Cr165 Cr94 Cr102 Cr83 Cr138 Cr112 Cr
Tax %27.6%27.1%27.5%25.8%27.0%25.3%27.7%26.1%25.7%25.7%25.6%25.6%
Net profit152 Cr138 Cr137 Cr103 Cr82 Cr91 Cr120 Cr70 Cr76 Cr62 Cr103 Cr84 Cr
EPS (₹)₹66.08₹59.79₹59.31₹44.90₹35.69₹40.00₹51.89₹30.18₹32.99₹26.79₹44.55₹36.26

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricDec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025TTM
Sales2,491 Cr2,771 Cr3,071 Cr2,902 Cr2,957 Cr2,770 Cr2,851 Cr2,013 Cr1,837 CrSign in free for the trailing twelve months
Operating expenses (approx.)1,954 Cr2,147 Cr2,405 Cr2,189 Cr2,194 Cr2,066 Cr2,047 Cr1,522 Cr1,346 CrSign in free for the trailing twelve months
EBITDA537 Cr624 Cr665 Cr713 Cr763 Cr704 Cr804 Cr491 Cr491 CrSign in free for the trailing twelve months
OPM %21.6%22.5%21.7%24.6%25.8%25.4%28.2%24.4%26.7%Sign in free for the trailing twelve months
Other income81 Cr90 Cr94 Cr90 Cr74 Cr72 Cr65 Cr17 Cr20 CrSign in free for the trailing twelve months
Interest1 Cr0.70 Cr0.30 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 CrSign in free for the trailing twelve months
Depreciation102 Cr103 Cr100 Cr82 Cr67 Cr42 Cr40 Cr37 Cr37 CrSign in free for the trailing twelve months
Profit before tax515 Cr610 Cr600 Cr677 Cr1,258 Cr864 Cr846 Cr563 Cr445 CrSign in free for the trailing twelve months
Tax %36.6%37.6%31.0%29.5%24.9%28.2%28.7%26.5%26.5%Sign in free for the trailing twelve months
Net profit326 Cr381 Cr414 Cr478 Cr944 Cr621 Cr603 Cr414 Cr327 CrSign in free for the trailing twelve months
EPS (₹)₹141.74₹165.48₹179.85₹207.38₹410.06₹269.47₹261.91₹179.00₹141.85Sign in free for the trailing twelve months
Dividend payout %———168.3%89.0%253.5%143.9%93.0%135.4%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricDec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Equity capital23 Cr23 Cr23 Cr23 Cr23 Cr23 Cr23 Cr23 Cr23 Cr
Reserves2,003 Cr2,196 Cr2,419 Cr2,096 Cr2,203 Cr1,253 Cr993 Cr838 Cr726 Cr
Borrowings—————————
Other liabilities751 Cr765 Cr802 Cr800 Cr835 Cr796 Cr700 Cr751 Cr506 Cr
Total liabilities2,777 Cr2,984 Cr3,244 Cr2,919 Cr3,061 Cr2,072 Cr1,715 Cr1,612 Cr1,255 Cr
Fixed assets (net)546 Cr548 Cr353 Cr357 Cr333 Cr305 Cr310 Cr311 Cr303 Cr
CWIP24 Cr16 Cr13 Cr6 Cr9 Cr19 Cr13 Cr18 Cr12 Cr
Investments0.20 Cr0.20 Cr0 Cr0 Cr0 Cr0 Cr2 Cr0 Cr0 Cr
Loans & advances—4 Cr2 Cr6 Cr5 Cr2 Cr2 Cr1 Cr0.90 Cr
Inventories416 Cr483 Cr470 Cr368 Cr392 Cr408 Cr664 Cr500 Cr312 Cr
Trade receivables194 Cr158 Cr224 Cr148 Cr143 Cr129 Cr132 Cr230 Cr177 Cr
Cash & bank722 Cr825 Cr1,120 Cr1,197 Cr1,538 Cr1,005 Cr393 Cr284 Cr263 Cr
Other assets875 Cr949 Cr1,064 Cr836 Cr641 Cr204 Cr199 Cr268 Cr188 Cr
Total assets2,777 Cr2,984 Cr3,244 Cr2,919 Cr3,061 Cr2,072 Cr1,715 Cr1,612 Cr1,255 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricDec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from operating activity435 Cr374 Cr412 Cr611 Cr559 Cr399 Cr231 Cr462 Cr438 Cr
Cash from investing-79 Cr-73 Cr66 Cr276 Cr631 Cr651 Cr36 Cr-19 Cr-11 Cr
Cash from financing-188 Cr-197 Cr-183 Cr-810 Cr-849 Cr-1,583 Cr-878 Cr-552 Cr-448 Cr
Net cash flow168 Cr104 Cr295 Cr78 Cr341 Cr-533 Cr-612 Cr-109 Cr-21 Cr
Free cash flow (OCF − Capex)378 Cr315 Cr337 Cr570 Cr536 Cr377 Cr197 Cr425 Cr413 Cr

Ratios

MetricDec 2023Dec 2024
ROCE %83.5%65.5%
ROE %59.4%48.0%
Debtor days1742
Inventory days428514
Days payable188418
Cash conversion cycle257138
OCF / EBITDA %28.7%94.0%
Debt / equity——
Current ratio1.921.76
Net debt / EBITDA-0.49-0.58